Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Mon, 1:30AM)
-
PR Newswire (Wed, 1:30AM)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 28, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
More Drama From Cell TherapeuticsM. E. Garza • Mon, Jan 30, 2012 -
-
-
-
-
Cell Therapeutics: FDA Approves Italian FactoryZacks Investment Research • Tue, Mar 9, 2010
-
-
-
-
-
-
Cell Therapeutics Starts Phase III Lung Cancer TrialSA Editor Susan Lerner • Mon, Sep 24, 2007
-
-
-
-
-
-
-
-
-
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Wed, Sep 12, 2012 -
-
-
-
-
-
-
-
-
-
-
-
Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)Fri, Aug 31, 2012
-
Cell Therapeutics, Inc. Q1 2010 Earnings Call TranscriptWed, Apr 28, 2010
-
Cell Therapeutics, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 18, 2008
-
PR Newswire (Mon, 1:30AM)
-
PR Newswire (Wed, 1:30AM)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Mar 11, 2013)
-
PR Newswire (Mar 4, 2013)
-
PR Newswire (Feb 28, 2013)
-
PR Newswire (Dec 10, 2012)
-
PR Newswire (Nov 12, 2012)
-
PR Newswire (Nov 12, 2012)
CTIC vs. ETF Alternatives
Company Description
We develop, acquire and commercialize novel treatments for cancer. Our goal is to build a leading biopharmaceutical company with a diversified portfolio of proprietary cancer drugs. Our research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways... More
